ROSEN, LEADING INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

New York, New York--(Newsfile Corp. - February 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • Feb 11, 2026

Alvotech Announces Increase in Number of Own Shares

REYKJAVIK,  ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Company's subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement.

GlobeNewsWire • Feb 11, 2026

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

NEW YORK, Feb. 9, 2026 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. So What: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PRNewsWire • Feb 9, 2026

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.

GlobeNewsWire • Feb 9, 2026

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

REYKJAVIK, ICELAND (February 5, 2026) – Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (PK) study for AVT80, a biosimilar candidate to Entyvio® (vedolizumab).

GlobeNewsWire • Feb 5, 2026

ROSEN, A LEADING NATIONAL FIRM, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

New York, New York--(Newsfile Corp. - February 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • Feb 4, 2026

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

New York, New York--(Newsfile Corp. - February 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • Feb 3, 2026

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.

GlobeNewsWire • Feb 2, 2026

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

New York, New York--(Newsfile Corp. - January 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • Jan 29, 2026

ROSEN, A LONGSTANDING LAW FIRM, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

New York, New York--(Newsfile Corp. - January 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • Jan 28, 2026